Skip to content

Retinal Function in Parkinson's Disease

Intrinsically Photosensitive Retinal Ganglion Cells in Parkinson's Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01010074
Enrollment
50
Registered
2009-11-09
Start date
2009-10-31
Completion date
2010-12-31
Last updated
2009-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

retina, Parkinson's disease, ganglion cell, pupillary

Brief summary

Parkinson's disease (PD) is a neurodegenerative disorder characterized by muscle rigidity, tremor, a slowing of physical movement (bradykinesia) and, in extreme cases, a loss of physical movement. The primary symptoms are the results of decreased stimulation of the motor cortex arising from the basal ganglia normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Secondary symptoms may include high level cognitive dysfunction and subtle language problems. Included in the symptomatology experienced by patients with PD, visual abnormalities are not uncommon. Visual changes among patients with PD appear not only dynamic in nature, but differentially affected based on the course of the disease and, perhaps more importantly, its treatment. Parkinson's disease has significant ramifications not only in observation of irregularities in vision, but how vision interacts with entrainment of the circadian clock. The purpose of this study is to examine the relationship between PD and operation of a unique set of retinal cells known to regulate the circadian clock and sleep-wake cycles in human subjects.

Interventions

None listed

Sponsors

US Department of Veterans Affairs
Lead SponsorFED

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

age 18-64 best corrected visual acuity of 20/25 or better in each eye -

Exclusion criteria

evidence of any form of eye disease, inability to understand and sign informed consent. \-

Design outcomes

Primary

MeasureTime frame
pupillary thresholdone

Countries

United States

Contacts

Primary ContactBruce Ira Gaynes, OD, PharmD
Bruce.Gaynes@va.gov708-216-6262
Backup ContactJasvinder Chawla, MD
Jasvinder.Chawla@va.gov708-202-3800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026